Logo image of AGFB.BR

AGFA-GEVAERT NV (AGFB.BR) Stock Fundamental Analysis

EBR:AGFB - Euronext Brussels - BE0003755692 - Common Stock - Currency: EUR

0.815  0 (-0.12%)

Fundamental Rating

2

Overall AGFB gets a fundamental rating of 2 out of 10. We evaluated AGFB against 12 industry peers in the Health Care Technology industry. While AGFB seems to be doing ok healthwise, there are quite some concerns on its profitability. AGFB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AGFB has reported negative net income.
In the past year AGFB has reported a negative cash flow from operations.
In the past 5 years AGFB reported 4 times negative net income.
AGFB had negative operating cash flow in 4 of the past 5 years.
AGFB.BR Yearly Net Income VS EBIT VS OCF VS FCFAGFB.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M

1.2 Ratios

Looking at the Return On Assets, with a value of -2.61%, AGFB is doing worse than 66.67% of the companies in the same industry.
AGFB has a Return On Equity of -9.76%. This is in the lower half of the industry: AGFB underperforms 66.67% of its industry peers.
AGFB's Return On Invested Capital of 0.29% is on the low side compared to the rest of the industry. AGFB is outperformed by 66.67% of its industry peers.
Industry RankSector Rank
ROA -2.61%
ROE -9.76%
ROIC 0.29%
ROA(3y)-6.95%
ROA(5y)0.93%
ROE(3y)-23.67%
ROE(5y)-5.43%
ROIC(3y)N/A
ROIC(5y)N/A
AGFB.BR Yearly ROA, ROE, ROICAGFB.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 100

1.3 Margins

With a Operating Margin value of 0.35%, AGFB is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
AGFB's Operating Margin has declined in the last couple of years.
AGFB has a worse Gross Margin (31.53%) than 75.00% of its industry peers.
In the last couple of years the Gross Margin of AGFB has remained more or less at the same level.
Industry RankSector Rank
OM 0.35%
PM (TTM) N/A
GM 31.53%
OM growth 3Y-17.71%
OM growth 5Y-24.95%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5Y-0.57%
AGFB.BR Yearly Profit, Operating, Gross MarginsAGFB.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 30

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AGFB is destroying value.
Compared to 1 year ago, AGFB has about the same amount of shares outstanding.
AGFB has less shares outstanding than it did 5 years ago.
AGFB has a worse debt/assets ratio than last year.
AGFB.BR Yearly Shares OutstandingAGFB.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
AGFB.BR Yearly Total Debt VS Total AssetsAGFB.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

AGFB has an Altman-Z score of 2.16. This is not the best score and indicates that AGFB is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.16, AGFB is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
AGFB has a Debt/Equity ratio of 0.40. This is a healthy value indicating a solid balance between debt and equity.
AGFB has a Debt to Equity ratio (0.40) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Altman-Z 2.16
ROIC/WACC0.03
WACC9.73%
AGFB.BR Yearly LT Debt VS Equity VS FCFAGFB.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.14 indicates that AGFB has no problem at all paying its short term obligations.
The Current ratio of AGFB (2.14) is better than 75.00% of its industry peers.
A Quick Ratio of 1.24 indicates that AGFB should not have too much problems paying its short term obligations.
The Quick ratio of AGFB (1.24) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.14
Quick Ratio 1.24
AGFB.BR Yearly Current Assets VS Current LiabilitesAGFB.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B

More info and screens

3

3. Growth

3.1 Past

AGFB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.23%, which is quite impressive.
AGFB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -25.77%.
Measured over the past years, AGFB shows a very negative growth in Revenue. The Revenue has been decreasing by -12.10% on average per year.
EPS 1Y (TTM)54.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-25.77%
Revenue growth 3Y-12.37%
Revenue growth 5Y-12.1%
Sales Q2Q%-0.35%

3.2 Future

AGFB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.13% yearly.
AGFB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.72% yearly.
EPS Next Y77.05%
EPS Next 2Y40.06%
EPS Next 3Y29.13%
EPS Next 5YN/A
Revenue Next Year1.04%
Revenue Next 2Y2.35%
Revenue Next 3Y2.72%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AGFB.BR Yearly Revenue VS EstimatesAGFB.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B 2B 2.5B
AGFB.BR Yearly EPS VS EstimatesAGFB.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AGFB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGFB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGFB.BR Price Earnings VS Forward Price EarningsAGFB.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AGFB is valued cheaper than 83.33% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 4.79
AGFB.BR Per share dataAGFB.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as AGFB's earnings are expected to grow with 29.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.06%
EPS Next 3Y29.13%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AGFB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGFA-GEVAERT NV

EBR:AGFB (3/7/2025, 7:00:00 PM)

0.815

0 (-0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-14 2024-11-14
Earnings (Next)03-12 2025-03-12/amc
Inst Owners52.83%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap126.18M
Analysts74
Price Target1.2 (47.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)22.97%
Min EPS beat(2)-96.08%
Max EPS beat(2)142.02%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-8.02%
Min Revenue beat(2)-11.52%
Max Revenue beat(2)-4.53%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-23.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.11
P/FCF N/A
P/OCF N/A
P/B 0.33
P/tB 0.92
EV/EBITDA 4.79
EPS(TTM)-0.65
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS7.29
BVpS2.45
TBVpS0.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.61%
ROE -9.76%
ROCE 0.39%
ROIC 0.29%
ROICexc 0.31%
ROICexgc 0.41%
OM 0.35%
PM (TTM) N/A
GM 31.53%
FCFM N/A
ROA(3y)-6.95%
ROA(5y)0.93%
ROE(3y)-23.67%
ROE(5y)-5.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-23.56%
ROICexcg growth 5Y-30.85%
ROICexc growth 3Y-23.57%
ROICexc growth 5Y-27.42%
OM growth 3Y-17.71%
OM growth 5Y-24.95%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5Y-0.57%
F-Score4
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Debt/EBITDA 3.26
Cap/Depr 95.35%
Cap/Sales 3.63%
Interest Coverage 0.25
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.14
Quick Ratio 1.24
Altman-Z 2.16
F-Score4
WACC9.73%
ROIC/WACC0.03
Cap/Depr(3y)56.62%
Cap/Depr(5y)51.62%
Cap/Sales(3y)2.44%
Cap/Sales(5y)2.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y77.05%
EPS Next 2Y40.06%
EPS Next 3Y29.13%
EPS Next 5YN/A
Revenue 1Y (TTM)-25.77%
Revenue growth 3Y-12.37%
Revenue growth 5Y-12.1%
Sales Q2Q%-0.35%
Revenue Next Year1.04%
Revenue Next 2Y2.35%
Revenue Next 3Y2.72%
Revenue Next 5YN/A
EBIT growth 1Y102.33%
EBIT growth 3Y-27.89%
EBIT growth 5Y-34.02%
EBIT Next Year241.58%
EBIT Next 3Y70.84%
EBIT Next 5YN/A
FCF growth 1Y61.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y97.7%
OCF growth 3YN/A
OCF growth 5YN/A